Product nameAnti-KRIT1 antibody
See all KRIT1 primary antibodies
DescriptionRabbit polyclonal to KRIT1
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Chicken, Cow, Zebrafish
Recombinant fragment, corresponding to a region within amino acids 419-593 of Human KRIT1 (O00522).
- 293T, A431, Jurkat and Raji whole cell lysates.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- Raji whole cell lysate (ab30124)
- Raji membrane extract lysate (ab30126)
- Jurkat whole cell lysate (ab30128)
- Jurkat membrane extract lysate (ab30130)
- A431 whole cell lysate (ab30132)
- A431 membrane extract lysate (ab30134)
- Jurkat whole cell lysate (ab7899)
- A431 whole cell lysate (ab7909)
- 293T whole cell lysate (ab95494)
Our Abpromise guarantee covers the use of ab126191 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 84 kDa.|
FunctionNegative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin D1 levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.
Tissue specificityLow levels in brain. Very weak expression found in heart and muscle.
Involvement in diseaseDefects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1) [MIM:116860]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
Sequence similaritiesContains 4 ANK repeats.
Contains 1 FERM domain.
Cellular localizationMembrane. Cell junction. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
- Information by UniProt
- Ankyrin repeat containing protein Krit1 antibody
- CAM antibody
- CCM 1 antibody
ab126191 has not yet been referenced specifically in any publications.